AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|

19.6 C

New York

Saturday, September 19, 2026

Fitch Ratings Initiates Coverage of Adecoagro with a BB Corporate Credit Rating and Stable Outlook

In HelloNation, Expert Chiropractor Dr. Craig Peterson Details How Quickly You Can Feel Relief After a Chiropractic Adjustment

Federal Reserve Rate Hike Reinforces Trend of Longer Vehicle Ownership

Tag: well

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

CIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Civitas Resources, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Civitas Resources, Inc. (“Civitas” or “the Company”) (NYSE: CIVI) and certain of its officers.

Announcement regarding the governance of Renault Group

Announcement regarding the governance
of Renault Group

China Trade ‘Deal’: U.S. Masterclass in Running Circles

In the grand theater of global economics, the U.S. and China have once again graced us with a riveting episode of "Let's Pretend We're...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

NSSC Investors with Losses Encouraged to Contact Hagens Berman Before June 24th Deadline in Securities Class Action

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

EQT sets target fund size for EQT XI at EUR 23 billion

THIS IS INFORMATION THAT EQT AB (PUBL) IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SUBMITTED FOR...

Redtiger Celebrates 5 Years of Bestselling Dash Cams for Cars With Discounts, Giveaways, and More

Marking five years of empowering drivers and vehicle owners to keep themselves and their passengers safe on the road, Redtiger is celebrating the anniversary with...

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsWell